A Phase 4 interventional study of Bazedoxifene Acetate and Placebo in Schizophrenia, Schizophreniform Disorders and Schizo Affective Disorder, sponsored by The Alfred. Recruiting at 1 site in Australia. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by The Alfred · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Schizophrenia with a site in Australia — 3 open to participants now, 5 under way, 1 of them phase 3. Schizophrenia · Australia.
Among the 46 studies in Schizophrenia with a site in Australia, this one is the 22nd largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 4, and was the 41st registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 46 studies in Schizophrenia with a site in Australia are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Australia, United States, Canada and 8 more countries
Ages 5–17
Swinburne University of Technology · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 167 across the 41 interventional studies, 866 across the 4 observational. Of the 38 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 46 have an industry lead sponsor. The 10 most frequent:
The Alfred is the lead sponsor of 47 studies on the registry; 4 are open to participants now.
The Alfred has 7 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
3 of the studies in Schizophrenia with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05982158Swinburne University of TechnologyAvatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices | 2026-12 |
| NCT03788811diaMentis Inc.ERG Components in Schizophrenia and Bipolar Disorder Type I | 2026-12-31 |
| NCT04113993The AlfredBazedoxifene -Treatment for Women With Schizophrenia | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies in Schizophrenia with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.
Despite advances in the treatment of schizophrenia, pharmacotherapy remains sub- optimal, and the prognosis for many patients is poor. We have pioneered work showing that estradiol has a positive role in the treatment of psychosis symptoms and cognitive deficits seen in people with schizophrenia. However, with the longer-term work from studies such as the Women's Health Initiative, it has become clear that long-term use of estradiol with progesterone may have associated increased risks of breast and other cancers. Hence, we began working with the Selective Estrogen Receptor Modulator - raloxifene, which appears to be safer for longer term use with respect to the development of breast and other cancers. Building on our and others work, raloxifene used as an adjunctive treatment in schizophrenia appears to produce inconsistent and varying responses in different sub-populations; gender, menopausal status, age, drug dose and delivery mode. We now propose to conduct a double-blind, randomized, placebo controlled trial of a third generation SERM - bazedoxifene - which is 4 times more selective for the alpha than the beta oestrogen receptor subtype. Bazedoxifene appears to be safer with respect to long term use than older SERMs, has additional actions on the glucocorticoid receptor, and together this different pharmacology speculatively has greater potential than other SERMs to impact favorably on both psychosis symptoms and cognition in men and women with schizophrenia. This study will test 160 women to determine if bazedoxifene, as an adjunctive hormone modulator, is effective for positive and cognitive symptoms of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Bazedoxifene dosed at 40 mg daily
Drug: Bazedoxifene Acetate
Identically packaged placebo capsule daily
Drug: Placebo
Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
Identically packaged placebo capsule daily
Schizophrenia symptoms
Psychopathology rating scales to quantify psychotic and affective symptoms (PANSS)
Time frame: 12 Weeks
Cognition
Cognitive test battery to quantify changes in cognitive functioning (MATRICS)
Time frame: 12 Weeks
Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.
Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 86 months is above that.
Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bazedoxifene
The Alfred